Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity.

Nanomedicine (London, England) Pub Date : 2024-01-01 Epub Date: 2024-09-03 DOI:10.1080/17435889.2024.2389770

Jacob A Medina, Debbie K Ledezma, Joshua Ghofrani, Jie Chen, Samantha J Chin, Preethi Bala Balakrishnan, Norman H Lee, Elizabeth E Sweeney, Rohan Fernandes

{"title":"Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity.","authors":"Jacob A Medina, Debbie K Ledezma, Joshua Ghofrani, Jie Chen, Samantha J Chin, Preethi Bala Balakrishnan, Norman H Lee, Elizabeth E Sweeney, Rohan Fernandes","doi":"10.1080/17435889.2024.2389770","DOIUrl":null,"url":null,"abstract":"Aim: We investigate combining Prussian Blue nanoparticles (PBNPs), as photothermal therapy (PTT) agents, with agonistic CD137 antibodies (αCD137) on a single nanoparticle platform to deliver non-toxic, anti-tumor efficacy in SM1 murine melanoma.Methods: We electrostatically coated PBNPs with αCD137 (αCD137-PBNPs) and quantified their physicochemical characteristics, photothermal and co-stimulatory capabilities. Next, we tested the efficacy and hepatotoxicity of PTT using αCD137-PBNPs (αCD137-PBNP-PTT) in SM1 tumor-bearing mice.Results: The αCD137-PBNPs retained both the photothermal and agonistic properties of the PBNPs and αCD137, respectively. In vivo, SM1 tumor-bearing mice treated with αCD137-PBNP-PTT exhibited a significantly higher survival rate (50%) without hepatotoxicity, compared with control treatments.Conclusion: These data suggest the potential utility of co-localizing PBNP-PTT with αCD137-based agonism as a novel combination nanomedicine.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2049-2064"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485692/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2389770","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/3 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: We investigate combining Prussian Blue nanoparticles (PBNPs), as photothermal therapy (PTT) agents, with agonistic CD137 antibodies (αCD137) on a single nanoparticle platform to deliver non-toxic, anti-tumor efficacy in SM1 murine melanoma.Methods: We electrostatically coated PBNPs with αCD137 (αCD137-PBNPs) and quantified their physicochemical characteristics, photothermal and co-stimulatory capabilities. Next, we tested the efficacy and hepatotoxicity of PTT using αCD137-PBNPs (αCD137-PBNP-PTT) in SM1 tumor-bearing mice.Results: The αCD137-PBNPs retained both the photothermal and agonistic properties of the PBNPs and αCD137, respectively. In vivo, SM1 tumor-bearing mice treated with αCD137-PBNP-PTT exhibited a significantly higher survival rate (50%) without hepatotoxicity, compared with control treatments.Conclusion: These data suggest the potential utility of co-localizing PBNP-PTT with αCD137-based agonism as a novel combination nanomedicine.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

光热疗法与CD137激动剂共定位可提高SM1黑色素瘤模型的存活率，且无肝毒性。

目的：我们研究了在单一纳米粒子平台上将普鲁士蓝纳米粒子（PBNPs）作为光热疗法（PTT）制剂与激动剂CD137抗体（αCD137）相结合，以在SM1小鼠黑色素瘤中发挥无毒的抗肿瘤疗效：我们在 PBNPs 上静电包覆了 αCD137 （αCD137-PBNPs），并对其理化特性、光热和协同刺激能力进行了量化。接着，我们使用αCD137-PBNPs（αCD137-PBNP-PTT）在SM1肿瘤小鼠中测试了PTT的疗效和肝毒性：结果：αCD137-PBNPs分别保留了PBNPs和αCD137的光热和激动特性。在体内，与对照组相比，接受αCD137-PBNP-PTT治疗的SM1肿瘤小鼠的存活率显著提高（50%），且无肝毒性：这些数据表明，将 PBNP-PTT 与基于 αCD137 的激动剂共定位作为一种新型组合纳米药物具有潜在的实用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量

期刊最新文献

Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma. Advances in Alzheimer's disease control approaches via carbon nanotubes. CD133-targeted afatinib nanomicelles for enhanced lung cancer theranostics. Correction. The emergence of inhalable RNA therapeutics and challenges faced - where to from here?